NASDAQ:ONCS OncoSec Medical Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OncoSec Medical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.37 0.00 (0.00 %) (As of 09/30/2020 02:32 PM ET) Add Compare Share Today's Range$3.26Now: $3.37▼$3.4550-Day Range$3.27MA: $3.78▼$4.5052-Week Range$1.04Now: $3.37▼$5.40Volume2,106 shsAverage Volume287,910 shsMarket Capitalization$77.62 millionP/E RatioN/ADividend YieldN/ABeta2.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer; and a collaborative research agreement with Duke University School of Medicine in HER2+ breast cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOncoSec Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.38, OncoSec Medical has a forecasted upside of 115.0% from its current price of $3.43.Amount of Analyst CoverageOncoSec Medical has only been the subject of 4 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesOncoSec Medical has received 305 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncoSec Medical has received 397 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncoSec Medical has received 56.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote “Outperform” if you believe ONCS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncoSec Medical does not currently pay a dividend.Dividend GrowthOncoSec Medical does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoSec Medical insiders have bought 59,145.38% more of their company's stock than they have sold. Specifically, they have bought $7,796,100.00 in company stock and sold $13,159.00 in company stock.Percentage Held by InsidersOnly 0.71% of the stock of OncoSec Medical is held by insiders.Percentage Held by InstitutionsOnly 4.03% of the stock of OncoSec Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OncoSec Medical are expected to grow in the coming year, from ($2.79) to ($1.41) per share.Price to Book Value per Share RatioOncoSec Medical has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.87 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCS Previous Symbol CUSIPN/A CIK1444307 Webwww.oncosec.com Phone855-662-6732Debt Debt-to-Equity Ratio0.31 Current Ratio2.97 Quick Ratio2.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-30,280,000.00 Net MarginsN/A Return on Equity-253.11% Return on Assets-145.57%Miscellaneous Employees33 Outstanding Shares23,032,000Market Cap$77.62 million Next Earnings Date10/5/2020 (Estimated) OptionableNot Optionable $3.37 0.00 (0.00 %) (As of 09/30/2020 02:32 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ONCS News and Ratings via Email Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter. OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions How has OncoSec Medical's stock been impacted by Coronavirus (COVID-19)? OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONCS stock has increased by 146.0% and is now trading at $3.37. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of OncoSec Medical? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoSec Medical. When is OncoSec Medical's next earnings date? OncoSec Medical is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for OncoSec Medical. How were OncoSec Medical's earnings last quarter? OncoSec Medical Inc (NASDAQ:ONCS) issued its quarterly earnings results on Monday, June, 15th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.01. View OncoSec Medical's earnings history. When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work? Shares of OncoSec Medical reverse split before market open on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for ONCS? 4 Wall Street analysts have issued 1-year price targets for OncoSec Medical's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate OncoSec Medical's stock price to reach $7.38 in the next year. This suggests a possible upside of 118.8% from the stock's current price. View analysts' price targets for OncoSec Medical. Are investors shorting OncoSec Medical? OncoSec Medical saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 219,400 shares, a drop of 32.3% from the August 15th total of 324,300 shares. Based on an average trading volume of 369,300 shares, the short-interest ratio is currently 0.6 days. View OncoSec Medical's Short Interest. Who are some of OncoSec Medical's key competitors? Some companies that are related to OncoSec Medical include CytomX Therapeutics (CTMX), IMV (IMV), Aldeyra Therapeutics (ALDX), Urovant Sciences (UROV), Concert Pharmaceuticals (CNCE), Cassava Sciences (SAVA), Immunic (IMUX), Osmotica Pharmaceuticals (OSMT), VYNE Therapeutics (VYNE), Selecta Biosciences (SELB), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), Affimed (AFMD), Arbutus Biopharma (ABUS) and Chiasma (CHMA). View all competitors. What other stocks do shareholders of OncoSec Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN). Who are OncoSec Medical's key executives? OncoSec Medical's management team includes the following people: Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer What is OncoSec Medical's stock symbol? OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS." How do I buy shares of OncoSec Medical? Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OncoSec Medical's stock price today? One share of ONCS stock can currently be purchased for approximately $3.37. How big of a company is OncoSec Medical? OncoSec Medical has a market capitalization of $77.62 million. OncoSec Medical employs 33 workers across the globe. What is OncoSec Medical's official website? The official website for OncoSec Medical is www.oncosec.com. How can I contact OncoSec Medical? OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
